{
    "info": {
        "nct_id": "NCT03707184",
        "official_title": "[18F]Fluciclovine Companion Imaging Study to Radium-223 and Radiotherapy in Hormone-Naive Men With Oligometastatic Prostate Cancer to Bone (RROPE) Study",
        "inclusion_criteria": "* Enrollment on IRB #102312 (A Phase 2 Study of Radium-223 and Radiotherapy in Hormone-Naive Men with Oligometastatic Prostate Cancer to Bone).\n* Patients must document their willingness to be followed for up to 24 months after recruitment by signing informed consent documenting their agreement to allow access to the data obtained on IRB #102312 and information and data entered into a research database.\n* All patients, or their legal guardians, must sign a written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization in accordance with institutional guidelines.\nHealthy volunteers allowed\nMust be MALE",
        "exclusion_criteria": "* Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals. Patients with significant drug or other allergies or autoimmune diseases may be enrolled at the Investigator?s discretion.\n* Patients who require monitored anesthesia for PET scanning.\n* Patients who are too claustrophobic to undergo PET scanning.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* All patients, or their legal guardians, must sign a written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization in accordance with institutional guidelines.",
            "criterions": [
                {
                    "exact_snippets": "All patients, or their legal guardians, must sign a written informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Health Insurance Portability and Accountability Act (HIPAA) authorization",
                    "criterion": "HIPAA authorization",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Enrollment on IRB #102312 (A Phase 2 Study of Radium-223 and Radiotherapy in Hormone-Naive Men with Oligometastatic Prostate Cancer to Bone).",
            "criterions": [
                {
                    "exact_snippets": "Enrollment on IRB #102312",
                    "criterion": "enrollment on IRB #102312",
                    "requirements": [
                        {
                            "requirement_type": "enrollment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Hormone-Naive Men",
                    "criterion": "hormone-naive status",
                    "requirements": [
                        {
                            "requirement_type": "hormone-naive",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Men",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "male"
                        }
                    ]
                },
                {
                    "exact_snippets": "Oligometastatic Prostate Cancer to Bone",
                    "criterion": "oligometastatic prostate cancer to bone",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": "oligometastatic prostate cancer to bone"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must document their willingness to be followed for up to 24 months after recruitment by signing informed consent documenting their agreement to allow access to the data obtained on IRB #102312 and information and data entered into a research database.",
            "criterions": [
                {
                    "exact_snippets": "document their willingness to be followed for up to 24 months after recruitment",
                    "criterion": "willingness to be followed for up to 24 months after recruitment",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "signing informed consent documenting their agreement to allow access to the data obtained on IRB #102312 and information and data entered into a research database",
                    "criterion": "informed consent for data access and research database entry",
                    "requirements": [
                        {
                            "requirement_type": "signed informed consent",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "agreement to allow access to data obtained on IRB #102312",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "agreement to allow information and data entered into a research database",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be MALE",
            "criterions": [
                {
                    "exact_snippets": "Must be MALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Patients who are too claustrophobic to undergo PET scanning.",
            "criterions": [
                {
                    "exact_snippets": "too claustrophobic to undergo PET scanning",
                    "criterion": "claustrophobia",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "too severe to undergo PET scanning"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who require monitored anesthesia for PET scanning.",
            "criterions": [
                {
                    "exact_snippets": "Patients who require monitored anesthesia for PET scanning",
                    "criterion": "requirement for monitored anesthesia for PET scanning",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals. Patients with significant drug or other allergies or autoimmune diseases may be enrolled at the Investigator?s discretion.",
            "criterions": [
                {
                    "exact_snippets": "Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals",
                    "criterion": "allergic or hypersensitivity reactions to previously administered radiopharmaceuticals",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "significant drug or other allergies or autoimmune diseases may be enrolled at the Investigator?s discretion",
                    "criterion": "significant drug or other allergies or autoimmune diseases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "investigator discretion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}